Universidad de Alcala de Henares, Madrid
Angiogenesis inhibitor dobesilate arrests glioma cell growth
Published in Managed Care Business Week, February 14th, 2006
According to recent research from Spain, "dihydroxy-2,5 benzene sulphonate (dobesilate) is used as an oral agent for treatment of vascular complications of diabetic retinopathy. We previously showed that blockade of fibroblast growth factor (FGF) driving angiogenesis with dobesilate inhibited new blood vessel formation in a mouse gelatine plug assay."
"In the present study we assessed the effects of dobesilate in rat glioma cells. Rat C6 cells line were grown as adherent cells in Dulbecco modified Eagle medium supplemented with 1% (v/v) fetal ovine serum and antibiotics. Calcium dobesilate...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Business Week
More Articles from Managed Care Business Week
- Business & Finance
The Quantum Group begins generating revenue through community health systems - Cutting Edge Information
Report finds early-stage pricing analysis leads to favorable reimbursement status - 5W Public Relations
Signalife, Inc. names New York-based public relations firm as agency of record - ALZA Corporation
Durogesic D-TRANS fentanyl system bioequivalent to original reservoir system - Alfred Hospital, Melbourne
Barriers to asthma guideline adherence are identified - Alliance for Consumer Education
Cold, flu threats don't worry moms - More from this issue of Managed Care Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
